William Blair analyst Myles Minter downgraded Praxis Precision Medicines to Market Perform from Outperform without a price target after the company’s Essential1 study evaluating ulixacaltamide for the treatment of essential tremor did not reach statistical significance.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PRAX:
- Praxis Precision Medicines to Present at Upcoming Investor Conferences
- Praxis Precision plunges as primary endpoint didn’t hit statistical significance
- Praxis Plummets on PRAX-944 Topline Data in Essential Tremor; Street Sees 482% Upside
- Praxis Precision Medicines Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3
- Praxis Precision Medicines announces results from Essential1 study